Samsung Biologics said on the 4th that it will participate in the 2026 JP Morgan Healthcare Conference (JPMHC), the world's largest pharmaceutical and biotech investment conference, to be held in San Francisco, U.S., from the 12th to the 15th (local time).
JPMHC is held every January and marks its 44th year. About 1,500 pharmaceutical, biotech, and healthcare corporations and more than 8,000 participants are expected to gather.
Samsung Biologics has received an official invitation for 10 consecutive years since 2017. At this conference, the corporations presentation will take place at 3 p.m. on the 13th in the Grand Ballroom at the main venue, The Westin St. Francis hotel.
Samsung Biologics is scheduled to present on the same day as GSK plc, AstraZeneca (AZ), and Eli Lilly.
Chief Executive John Rim will deliver the presentation. The topic links the recently launched contract manufacturing organization (CMO) brand "ExellenS" with Samsung Biologics' core value "4E (Excellence)." In the presentation, Rim is expected to explain last year's results, this year's business plan and mid- to long-term strategy, and the background of competitiveness and growth.
Samsung Biologics is pursuing a strategy to expand production capacity, business portfolio, and regional bases. Last year, it completed a spin-off with Samsung Bioepis Holdings to transition into a pure contract development and manufacturing organization (CDMO) and acquired the Rockville plant in Maryland, U.S. Based on this, cumulative orders last year surpassed $20 billion.
A Samsung Biologics official said, "At this conference, we plan to highlight our global CDMO competitiveness through meetings with investors and potential client corporations and focus on networking for business expansion."